IITs: The New Regulatory Frontier

Investigator-Initiated Trials (IITs) are no longer just for academic exploration. Today, these studies drive early clinical signals for oncology, rare diseases, and advanced therapies and drug-repurposing programs. From our own experience, well-governed investigator-led studies can shape the strategic direction of major sponsor-led development programs, financing discussions, and licensing strategy.

However, as the strategic value of IIT data increases, global regulatory scrutiny intensifies. Health authorities across the globe are pivoting to ask a very specific, critical question: Is this IIT data actually reliable enough to support development or a formal regulatory decision?

In this edition of PharmaFocus, we explore how the United States, the European Union, Japan, and China regulate IITs, how sponsor and investigator responsibilities differ by market, and why cost strategy cannot be separated from regulatory strategy. The focus is primarily on drug, biologic, medicinal product, and advanced-therapy IITs; device-only studies, IVD performance studies, purely observational studies, and non-interventional real-world evidence projects may follow different pathways and should be assessed separately.

United States: The Sponsor-Investigator Dual Role

In the US, the regulatory framework for a drug or biologic IIT hinges on the Investigational New Drug (IND) regulations. Under 21 CFR Part 312, the key legal concept is the sponsor-investigator: an individual who both initiates and conducts the investigation and assumes both sponsor and investigator obligations. Device-based IITs require a separate IDE/significant-risk/non-significant-risk analysis under 21 CFR Part 812.

Crucially, this dual role does not split the liability. The individual assumes the full legal and operational responsibilities of both the sponsor (e.g., protocol design, safety reporting, FDA correspondence) and the investigator (e.g., site conduct, IRB approvals, patient consent).

• The IND Exemption Pathway: The FDA does offer a specific pathway to conduct an IIT without submitting an IND, but it is strictly limited. To qualify for an IND exemption under 21 CFR 312.2(b), the study must use a lawfully marketed drug and meet all of the following criteria:
  • The investigation is not intended to support a new indication or a significant change in the product labeling.
  • The data will not be used to support a significant change in the advertising for the product.
  • The study does not involve a route of administration, dosage level, or patient population that significantly increases the risks associated with the drug.
  • The trial is conducted in strict compliance with Institutional Review Board (IRB) review and informed consent regulations.

If the IIT fails to meet even one of these criteria, the sponsor-investigator must formally submit and maintain an active IND under 21 CFR Part 312 before proceeding.

Strategic Takeaway: Define your IND strategy before enrollment begins. If a commercial sponsor provides funding, product, or expects future data rights, explicit contracts must outline all regulatory, safety, and oversight responsibilities from day one. Unclear boundaries jeopardize compliance and can permanently destroy the data’s future regulatory value.

European Union: CTIS and the End of Informal Academic Exemptions

The EU operates under a harmonized framework via the Clinical Trials Regulation (EU) No 536/2014 (CTR) and the Clinical Trials Information System (CTIS). For IIT sponsors, the most critical realization is that the EU does not offer blanket exemptions for academic or non-commercial research. If a study is classified as an interventional clinical trial involving an investigational medicinal product, it must be submitted through CTIS and comply with the CTR framework, regardless of who is running it.

• The Low-Intervention Pathway: The CTR differentiates trials based on risk rather than sponsor type. An IIT may qualify for a streamlined regulatory pathway if it is classified as a low-intervention clinical trial. To meet this definition under Article 2(2)(3) of the CTR, the study must satisfy all of the following:
  • The investigational medicinal products are authorized for the market (excluding placebos).
  • According to the protocol, the products are used in accordance with the terms of the marketing authorization, or their use is evidence-based and supported by published scientific evidence.
  • The additional diagnostic or monitoring procedures pose only minimal additional risk or burden to the subjects compared to normal clinical practice.

Strategic Takeaway: Do not assume academic means exempt. When partnering with EU institutions, verify that the legal sponsor has fully costed and resourced CTIS submission, safety reporting, transparency postings, lay-summary obligations, GDPR/data-transfer controls, and archiving. If these obligations are under-resourced, the resulting data may create avoidable GCP inspection and reliance risks in a future EU development or marketing application strategy.

Japan’s Dual Pathway: PMD Act-Regulated Chiken or Clinical Research?

Japan’s regulatory framework for clinical trials relies on a unique dual-pathway system that categorizes studies based primarily on their ultimate regulatory intent rather than the sponsor’s identity.

• The Registration Pathway: If the intent of the clinical trial is to collect data to support a marketing authorization application submitted to the PMDA/MHLW, the study should be conducted as a PMD Act-regulated chiken (治験). This applies regardless of whether the sponsor is a pharmaceutical company or a sponsor-investigator. A chiken must comply with the Pharmaceuticals and Medical Devices Act and Japan’s Ministerial Ordinance on Good Clinical Practice.
• The Research Pathway: If the study is not intended for regulatory registration, it may fall under the Clinical Trials Act and related ethical framework rather than the PMD Act/GCP chiken framework. Specified clinical research is particularly relevant where a study involves unapproved/off-label use or funding from a marketing authorization holder with an interest in the product; it generally requires review by a certified clinical research review board and registration in the Japan Registry of Clinical Trials (jRCT).

Strategic Takeaway: You must prospectively choose your regulatory lane in Japan as intent dictates your pathway. Attempting to retroactively bridge academic research data from a Specified Clinical Trial to support a future PMDA marketing application is a high-risk strategy that rarely succeeds without preemptive, formal consultation with the PMDA.

China: Institutional Governance Takes Center Stage

Historically, investigator-initiated research in China operated with substantial local institutional variation. That changed with the 2024 Measures for Medical and Health Institutions to Conduct Investigator-Initiated Clinical Research, issued by the National Health Commission and related authorities. The Measures expressly address clinical research conducted in medical institutions that is not intended to support the registration of drugs, medical devices, or in vitro diagnostic reagents.

China’s regulatory landscape is now strictly bifurcated based on the study’s purpose and the nature of technology:

• Institutional Research (Non-Registration): If an IIT is conducted strictly to improve diagnostic or treatment protocols and is not intended to support a drug or device registration, it is governed by the hospital or medical institution under the 2024 Measures. The medical institution serves as the ultimate accountable body and must enforce:
  • Scientific and ethical review prior to initiation.
  • Formal registration in the National Medical Research Registration and Filing Information System.
  • Financial auditing and strict management of research funds.
  • Data security protocols, including human genetic resource administration.
  • Manage adverse events and source data, keep study information current, and retain research records for at least 10 years after study completion.

However, these are institutional governance requirements. They do not, by themselves, confer NMPA registration status on the resulting data.

• Registration-Directed Trials: If an investigator or an industry sponsor intends to use the trial data to support an NMPA marketing authorization, the 2024 Measures do not apply. The study immediately defaults to a formal Drug Clinical Trial. It requires an NMPA IND approval and must strictly adhere to the updated NMPA Good Clinical Practice (GCP) framework (takes effect on 01 Sep 2026).
• The Biomedical New Technology Route (2026): As of May 1, 2026, the Regulation on the Administration of Clinical Research and Clinical Translational Application of Biomedical New Technologies (Order No. 818) adds a separate pathway for certain biomedical new technologies. Initiating institutions and research institutions must determine whether the biomedical-new-technology path or the drug/device regulatory path applies. If the drug or device path is selected, drug and device regulatory rules apply, and duplicative pathway use should be avoided. This regime emphasizes heightened risk management, ethics review, adverse-event handling, data management, participant protection, and traceability.

Strategic Takeaway: Do not assume that a medical-institution IIT can later be upgraded into a registration trial. If a commercial sponsor expects Chinese hospital-generated data to support a future NMPA, FDA, EMA, or PMDA strategy, the intended evidentiary use must be mapped before initiation. For advanced therapies, the critical first step is pathway selection: NMPA drug/device clinical trial requirements versus the biomedical new technology clinical research/translational application route.

The Cost Dimension: IITs, Early-Phase Development, and Regional Strategy

Cost is one of the main reasons sponsors and investors support IITs, especially in rare disease, oncology, repurposing, and advanced-therapy programs where early human signal can determine whether a program is financed, licensed, redesigned, or stopped. The economic value is not that an IIT is a lower-standard substitute for a sponsor-led Phase 1 or Phase 2 trial. The value is that a well-designed IIT can answer a focused development question before the sponsor commits to the full infrastructure, geography, and capital burden of a conventional early-phase program.

Conventional sponsor-led early-phase trials remain expensive because the sponsor is paying not only for patient care and testing, but also for regulatory submissions, monitoring, pharmacovigilance, data management, statistics, clinical operations, CMC/product accountability, quality systems, vendor oversight, and inspection readiness. A widely cited U.S. clinical-trial cost analysis estimated Phase 1 study costs at approximately $1.4 million to $6.6 million per study, depending on therapeutic area, and Phase 2 study costs at approximately $7.0 million to $19.6 million per study. More recent U.S. government-sponsored drug-development analysis shows that clinical trials represent the largest portion of out-of-pocket drug development cost, accounting for approximately 68% of out-of-pocket R&D expenditures.

By contrast, IIT budgets can be substantially lower when the study is exploratory, single-center, operationally streamlined, or supported by institutional infrastructure. Based on BLA Regulatory’s internal analysis of public China procurement examples and industry benchmarks, small exploratory IITs may fall in the approximate $120,000 to $440,000 range, medium multicenter IITs in the approximate $440,000 to $1.16 million range, and large multicenter or long-follow-up IITs may exceed $1.4 million. These figures should be treated as planning benchmarks rather than universal tariffs. Supporting public cases include a Shenzhen Bay Laboratory IIT CMC service procurement budget of RMB 950,000 (approximately $138,000), a Shenzhen Bay Laboratory IIT CRO transaction amount of RMB 855,525 (approximately $124,000), and a large multicenter IL-23 monoclonal antibody psoriasis IIT at Shenzhen Nanshan Hospital with reported project funding of RMB 10 million (approximately $1.45 million). Actual costs vary by region, product class, indication, sample size, follow-up, testing intensity, manufacturing complexity, data-quality expectations, and whether the sponsor provides free drug or funds CRO/SMO services.

A practical cost comparison is therefore best framed as a decision tool rather than a fixed price list:

The regional cost logic is also different. In the United States, IITs may reduce direct sponsor spend, but legal, safety, monitoring, IRB, contracting, data access, and product liability expectations remain substantial. In the EU, CTIS, transparency, GDPR, and Member State coordination can add administrative costs even for non-commercial sponsors. In Japan, the cost advantage depends heavily on whether the study remains clinical research or becomes PMD Act-regulated chiken. In China, medical institutions may be more willing to participate in investigator-led or collaborative innovation models, and hospital/labor/CMC costs may be lower than U.S. or Western European benchmarks; however, human genetic resources, cross-border data/sample transfer, product-control, and pathway-selection requirements can create material compliance costs.

For innovative biologics, cell therapy, and gene therapy, the cost discussion must also include financing and business-development value. A well-governed IIT can create early clinical credibility that supports fundraising, licensing, or global development discussions. A poorly governed IIT can do the opposite: it can generate an uninterpretable or negative signal, create safety-reporting uncertainty, or force the sponsor to repeat the study under a formal IND/CTA pathway. The cost of an IIT should therefore be judged against the cost of the decision it is meant to de-risk.

Final Perspective

IITs remain one of the most important drivers of clinical innovation. They can generate early signals, explore new indications, support biomarker research, and create development opportunities where traditional sponsor-led programs may be slower or more difficult to execute.

The strongest IIT strategy ideally starts before trial initiation. Sponsors and investigators should classify the study correctly, define accountability, control the product, design the protocol around the intended future decision, and make the records inspectable. In today’s environment, the best question is not “Will regulators accept IIT data?” The better question is “Have we built this IIT so regulators can rely on it?”